Ovagen
Research OnlyAlso known as: EDL, Glu-Asp-Leu, Hepatic tripeptide, Liver bioregulator
A synthetic tripeptide (Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for liver support. Part of the peptide bioregulation framework claiming tissue-specific gene regulation. No Western clinical validation exists.
Research Statistics
Russian bioregulator with exclusively Khavinson institute research; no independent Western replication and hepatoprotective mechanism remains theoretical.
Research Dossier
Overview
What is Ovagen and what does the research say?
Mechanism of Action
Ovagen (Glu-Asp-Leu) is proposed to regulate liver tissue through peptide bioregulation mechanisms developed by Vladimir Khavinson.
Proposed Mechanisms
- Hepatocyte Gene Modulation - Claimed to interact with DNA/chromatin in liver cells to regulate gene expression
- Regenerative Support - Proposed to support hepatocyte regeneration processes
- Metabolic Regulation - Claimed effects on liver metabolic enzyme expression
Important Limitations
- No Western clinical validation or regulatory approval
- All research originates from Russian institutions
- Proposed tissue-specificity mechanisms lack clear scientific explanation
- No controlled human clinical trials
How It Works (Simplified)
Ovagen targets liver function through hepatocyte modulation:
Proposed to stimulate hepatocyte function, promoting liver cell regeneration and metabolic activity that may decline with age or damage.
Short peptides like EDL are claimed to penetrate cell nuclei and interact with DNA/chromatin, potentially affecting liver-related gene expression.
Russian studies claim effects on hepatocyte regeneration, supporting liver tissue repair, though mechanisms are not well characterized.
Proposed to modulate liver enzyme expression affecting metabolic processes including detoxification and protein synthesis.
Scientific Pathways
Hepatocyte Stimulation Pathway (Liver Support)
Ovagen (EDL) → Hepatocyte Interaction → Gene Expression Changes
↓
Hepatocyte Regeneration & Function
↓
Enhanced Liver Metabolic CapacityEpigenetic Modulation Pathway (Gene Expression)
Ovagen → Nuclear Penetration → Chromatin/Histone Interaction → Gene Activation
↓
Liver-Specific Gene Expression ChangesNote: These pathways are theoretical constructs based on Russian preclinical research. No independent Western validation confirms these mechanisms in humans.
Research Overview
Evidence for Ovagen consists primarily of Russian preclinical studies. The peptide bioregulation theory proposes that short peptides can selectively regulate gene expression in specific tissues, though this mechanism remains unvalidated by Western research standards.
Evidence Quality: Very Low
- Limited to Russian institutional studies
- No independent Western replication
- No randomized controlled human trials
- Mechanism of tissue specificity unexplained
Important Limitations
- 100% of research from Russian institutes (primarily St. Petersburg Institute of Bioregulation and Gerontology)
- No independent Western replication or validation studies
- No controlled human clinical trials demonstrating hepatoprotective benefits
- Mechanism of action for a simple tripeptide affecting liver function is not fully characterized
- Pharmacokinetics, bioavailability, and optimal dosing in humans are unknown
- Comparison to established hepatoprotective agents shows substantial evidence gap
- Translation from animal studies to human liver benefits is completely unconfirmed
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on preclinical data: Initial interactions with hepatic tissue may begin. In vitro studies suggest cellular uptake in liver cells. Any liver function parameter changes would not be detectable this early.
Russian protocols suggest continued treatment during this period. Animal studies show progressive changes in hepatocyte function over weeks. Gene expression modifications may develop.
Extended treatment in animal models shows more pronounced effects on liver regeneration markers. Human response timeline is unknown.
Long-term effects based on Russian animal studies using cyclical treatment protocols. Optimal human treatment duration and cycling are not established. Sustained hepatoprotective benefits are unconfirmed.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Ovagen product quality
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Ovagen with other peptides. Based on published research and mechanistic considerations.
Livagen
CompatibleBoth target liver function - Livagen (KED) and Ovagen (EDL) represent different tripeptide approaches to hepatic support within Khavinson bioregulator research.
Epithalon
CompatibleBoth Khavinson bioregulator peptides with distinct targets - Ovagen for liver, epithalon for pineal/longevity.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Ovagen
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Cardiogen
AED, Ala-Glu-Asp, Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp) developed by Russian scientist Vladimir Khavinson for cardiac tissue support. Claimed to target cardiomyocyte gene expression and provide cardioprotective effects. No Western clinical validation exists; evidence limited to Russian preclinical and observational studies.
Chonluten
EDG-GI, Glu-Asp-Gly (GI), GI tract tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01, Evaxion EVX-01, AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1 data in melanoma showed 67% overall response rate when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.